Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 302

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma

Open access
Shoushtari, Alexander N., Munhoz, Rodrigo R., Kuk, Deborah, Ott, Patrick A., Johnson, Douglas B., Tsai, Katy K., Rapisuwon, Suthee, Eroglu, Zeynep, Sullivan, Ryan J., Luke, Jason J., Gangadhar, Tara C., Salama, April K. S., Clark, Varina, Burias, Clare, Puzanov, Igor, Atkins, Michael B., Algazi, Alain P., Ribas, Antoni, Wolchok, Jedd D., Postow, Michael A.·2016·Cancer

Abstract

BACKGROUND: Therapeutic antibodies against programmed cell death receptor 1 (PD‐1) are considered front‐line therapy in metastatic melanoma. The efficacy of PD‐1 blockade for patients with biologically distinct melanomas arising from acral and mucosal surfaces has not been well described. METHODS: A multi‐institutional, retrospective cohort analysis identified adults with advanced acral and mucosal melanoma who received treatment with nivolumab or pembrolizumab as standard clinical practice through expanded access programs or published prospective trials. Objective responses were determined using investigator‐assessed Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progression‐free survival and overall survival were assessed using the Kaplan‐Meier method. RESULTS: Sixty individuals were identified, including 25 (42%) with acral melanoma and 35 (58%) with mucosal melanoma. Fifty‐one patients (85%) had received previous therapy, including 77% who had previously received ipilimumab. Forty patients (67%) received pembrolizumab at a dose of 2 mg/kg or 10 mg/kg, and 20 (33%) received nivolumab at a doses ranging from 0.3 to 10 mg/kg every 2 to 3 weeks. The objective response rate was 32% (95% confidence interval, 15%‐54%) in patients with acral melanoma and 23% (95% confidence interval, 10%‐40%) in those with mucosal melanoma. After a median follow‐up of 20 months in the acral melanoma group and 10.6 months in the mucosal melanoma group, the median progression‐free survival was 4.1 months and 3.9 months, respectively. Only 2 patients (3%) discontinued treatment because of toxicity. CONCLUSIONS: Response rates to PD‐1 blockade in patients with acral and mucosal melanomas were comparable to the published rates in patients with cutaneous melanoma and support the routine use of PD‐1 blockade in clinical practice. Further investigation is needed to identify the mechanisms of response and resistance to therapy in these subtypes. Cancer 2016;122:3354–3362. © 2016 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.30259

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 302

Metadata

Authors
Shoushtari, A. N., Munhoz, R. R., Kuk, D., Ott, P. A., Johnson, D. B., Tsai, K. K., Rapisuwon, S., Eroglu, Z., Sullivan, R. J., Luke, J. J., Gangadhar, T. C., Salama, A. K. S., Clark, V., Burias, C., Puzanov, I., Atkins, M. B., Algazi, A. P., Ribas, A., Wolchok, J. D., & Postow, M. A.
Venue
Cancer
Publisher
Wiley
Published
2016-08-17
Volume
122
Issue
21
Pages
3354-3362
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2519469881
Cited by
302
References
34
FWCI
12.05
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma. https://app.cochat.ai/papers/10.1002/cncr.30259
The paper
Shoushtari, A. N., Munhoz, R. R., Kuk, D., Ott, P. A., Johnson, D. B., Tsai, K. K., Rapisuwon, S., Eroglu, Z., Sullivan, R. J., Luke, J. J., Gangadhar, T. C., Salama, A. K. S., Clark, V., Burias, C., Puzanov, I., Atkins, M. B., Algazi, A. P., Ribas, A., Wolchok, J. D., & Postow, M. A. (2016). The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma. Cancer. https://doi.org/10.1002/cncr.30259

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.